{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470612573
| IUPAC_name = Propan-2-yl 7-[3,5-dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl)<br>phenoxy]-but-1-enyl]-cyclopentyl]hept-5-enoate
| image = Travoprost structure.svg
<!--Clinical data-->
| tradename = Travatan
| Drugs.com = {{drugs.com|monograph|travoprost}}
| MedlinePlus = a602027
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = Rx-only
| legal_status = 
| routes_of_administration = Topical ([[eye drop]]s)
<!--Pharmacokinetic data-->
| bioavailability   = 
| protein_bound     = 
| metabolism        = Activation by ester [[hydrolysis]], deactivation by [[beta oxidation]], OH-[[oxidation]], double bond reduction
| metabolites       = 
| onset             = 2 hours
| elimination_half-life = 1.5 hours (in [[aqueous humour|aqueous fluid]])<br/>45 minutes (terminal)
| duration_of_action= ≥ 24 hours
| excretion         = Mainly via kidney
<!--Identifiers-->
| IUPHAR_ligand = 7102
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 157283-68-6
| ATC_prefix = S01
| ATC_suffix = EE04
| ATC_supplemental =  
| PubChem = 5282226
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00287
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4445407
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = WJ68R08KX9
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01964
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 746859
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200799
<!--Chemical data-->
| C=26 | H=35 | F=3 | O=6
| molecular_weight = 500.548 g/mol
| smiles = FC(F)(F)c2cc(OC[C@H](O)/C=C/[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(=O)OC(C)C)ccc2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MKPLKVHSHYCHOC-AHTXBMBWSA-N
}}

'''Travoprost''' ophthalmic solution is a topical medication used for controlling the progression of [[glaucoma]] or [[ocular hypertension]], by reducing [[intraocular pressure]]. It is a synthetic [[Prostaglandin analogue|prostaglandin analog]] (or more specifically, an [[Functional analog (chemistry)|analog]] of [[Prostaglandin F2alpha|prostaglandin F<sub>2α</sub>]])<ref name="MedlineTravatan">{{Cite web|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=338e7ff4-0d91-4208-a45d-bfa2be52334d|title=Travatan - travoprost solution|author=Alcon Laboratories, Inc.|work=DailyMed|publisher=U.S. National Library of Medicine|location=Bethesda, MD|date=September 2011|accessdate=2011-09-30}}</ref><ref name="MedlineTravatanZ">{{Cite web|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5549684b-1724-45ca-b67b-590c62b7c149|title=Travatan Z (travoprost) solution|author=Alcon Laboratories, Inc.|work=DailyMed|publisher=U.S. National Library of Medicine|location=Bethesda, MD|date=September 2011|accessdate=2011-09-30}}</ref> that works by increasing the outflow of [[aqueous humor|aqueous fluid]] from the [[human eye|eye]]s.<ref name="MedlinePlusTravoprost">{{Cite web|url=http://www.nlm.nih.gov/medlineplus/druginfo/meds/a602027.html|title=Travoprost Ophthalmic|author=AHFS Consumer Medication Information|work=MedlinePlus|publisher=U.S. National Library of Medicine|location=Bethesda, MD|date=2011-01-01|accessdate=2011-09-30}}</ref> It is also known by the brand names of '''Travatan''' and '''Travatan Z''', manufactured by [[Alcon]].

==Side effects==
Possible side effects are:<ref name="AC">{{cite book|title=Austria-Codex|at=Travatan 40&nbsp;Mikrogramm/ml Augentropfen|editor=Haberfeld, H|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2015|language=German}}</ref>
* blurred vision
* eyelid redness
* permanent darkening of eyelashes
* eye discomfort
* permanent darkening of the [[Iris (anatomy)|iris]] to brown ([[heterochromia]])
* burning sensation during use
* thickening of the eyelashes
* inflammation of the [[Prostate|prostate gland]], restricting urine flow ([[Benign prostatic hyperplasia|BPH]]){{fact|date=July 2016}}

Research suggests that wiping the eye with an absorbent pad after the administration of eye drops can result in shorter eyelashes and a lesser chance of hyperpigmentation in the eyelid, compared to not wiping off excess fluid.<ref name="Xu">{{cite journal |author=Xu L, Wang X, Wu M |title= Topical medication instillation techniques for glaucoma |journal=Cochrane Database Syst Rev|volume= |issue=2|pages= CD010520 |date=2017 |pmid= 28218404|doi= 10.1002/14651858.CD010520.pub2}}</ref>

==Pharmacology==
===Mechanism of action===
Like other analogs of prostaglandin F<sub>2α</sub> such as [[tafluprost]] and [[latanoprost]], travoprost is an [[ester]] [[prodrug]] of the free acid, which acts as an [[agonist]] at the [[prostaglandin F receptor]], increasing outflow of aqueous fluid from the eye and thus lowering intraocular pressure.<ref name="AC" />

===Pharmacokinetics===
Travoprost is absorbed through the [[cornea]], where it is [[hydrolyse]]d to the free travoprost acid. Highest concentrations of the acid in the eye are reached one to two hours after application, and its half-life in the aqueous fluid is 1.5 hours. Once it reaches the bloodstream, it is quickly metabolised, so that concentrations in the system do not exceed 25 [[picogram|pg]]/ml (compared to 20 ng/ml in the eye, which is higher by nearly a factor of 1000).<ref name="AC" />

Metabolites are formed by [[beta oxidation]] of the acidic chain (compare [[Tafluprost#Pharmacokinetics]]), [[oxidation]] of the [[hydroxyl|OH]]-group in the other side chain, and reduction of the double bond next to this OH-group. Travoprost acid and its metabolites are mainly excreted via the kidney<ref name="AC" /> with a terminal half-life of 45 minutes.<ref>[[Drugs.com]]: Travoprost {{drugs.com|monograph|travoprost}}.</ref>

[[File:Travatan.jpg|thumb|left|One 2.5 ml dropperette of Travatan]]

==References==
{{Reflist}}

{{Antiglaucoma preparations and miotics}}
{{Prostaglandins}}
{{Prostanoidergics}}

[[Category:Prostaglandins]]
[[Category:Trifluoromethyl compounds]]